Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
EXTON, Pa., May 03, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent operational highlights on Thursday, May 10, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 3897293 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484-713-6133
[email protected]
